Lactiplantibacillus plantarum WJL enhances low-protein diet efficacy in chronic kidney disease
Lactiplantibacillus plantarum WJL supplementation improved metabolic outcomes in CKD patients on a low-protein diet.
Phase III
chronic kidney disease (CKD) patients
Status
Active
Sponsor
pharma companies in nephrology
Signal Score
8.2
Signal assessment
Signal strength
high
Confidence level
moderate
Why it matters
The findings on Lactiplantibacillus plantarum WJL suggest a promising adjunctive therapy for chronic kidney disease management, particularly in enhancing the efficacy of low-protein diets. This could lead to new product development opportunities and differentiation in treatment strategies within the nephrology market.
Recommended action
Humanexa recommends Monitor.
Analysis
Monitor upcoming clinical trials validating the role of Lp WJL in CKD management and its integration into dietary guidelines.
Related companies & assets
Companies
Assets
Sources & Humanexa intelligence
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.